Biogen Inc
NASDAQ:BIIB
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
155.43
267.71
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Biogen Inc
Biogen Inc
Gross Profit
Biogen Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biogen Inc
NASDAQ:BIIB
|
Gross Profit
$7.3B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-1%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$37.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$22B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$9.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
24%
|
CAGR 10-Years
29%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$12B
|
CAGR 3-Years
1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
|
Biogen Inc
Glance View
Biogen Inc. is a renowned biotechnology company that has carved out a niche in the development and delivery of groundbreaking therapies for neurological diseases. Founded in 1978, the company has focused on addressing some of the most challenging and complex health conditions, particularly multiple sclerosis (MS) and Alzheimer’s disease. With a robust pipeline of innovative treatments, Biogen aims to improve the lives of individuals affected by debilitating neurological disorders. Its flagship products, including drugs such as Tecfidera and Avonex, have notably solidified Biogen's reputation as a leader in MS treatment, contributing significantly to its revenue stream and positioning the company as a pivotal player in the biopharmaceutical landscape. In recent years, Biogen has expanded its focus to tackle Alzheimer’s disease, with the controversial introduction of Aduhelm, the first new Alzheimer’s treatment in nearly two decades. This move has drawn both attention and scrutiny from investors and healthcare professionals alike, highlighting the intense debates around pricing, efficacy, and regulatory oversight in the biotech sector. As Biogen continues to innovate, it is also making strides in strategic partnerships and collaborations to enhance its research capabilities and broaden its therapeutic offerings. With a strong commitment to enhancing patient outcomes and a growing reputation for scientific excellence, Biogen presents a compelling investment opportunity, albeit with the inherent risks associated with the dynamic and rapidly evolving field of biotechnology.
See Also
What is Biogen Inc's Gross Profit?
Gross Profit
7.3B
USD
Based on the financial report for Sep 30, 2024, Biogen Inc's Gross Profit amounts to 7.3B USD.
What is Biogen Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
-1%
Over the last year, the Gross Profit growth was -3%. The average annual Gross Profit growth rates for Biogen Inc have been -7% over the past three years , -10% over the past five years , and -1% over the past ten years .
You don't have any saved screeners yet
